Posts

Posted on

Cummins Introduces New Heavy-Duty Powertrain for Natural Gas Customers

Cummins Introduces New Heavy-Duty Powertrain for Natural Gas Customers

COLUMBUS, Ind.–(BUSINESS WIRE)–
Global power leader Cummins Inc. (NYSE: CMI) and Cummins Westport Inc. announced today that the ISX12N+Endurant HD N powertrain from its Integrated power portfolio is now available for heavy-duty customers, delivering a fully integrated natural gas powertrain. The combination of the ISX12N near zero natural gas engine and the Endurant HD N 12-speed automated transmission from Eaton Cummins Automated Transmission Technologies is well suited for heavy-duty regional haul fleets looking to lower emissions and improve their sustainability profile.

“The ultra-low emissions of the ISX12N combined with the Endurant HD N transmission provides the optimal powertrain solution for customers working to lower their carbon footprint,” said Thomas R. Hodek, President of Cummins Westport. “The deep powertrain integration delivers improved launch, low speed maneuverability, and smoother shifts that drivers will appreciate.”

When paired with the Endurant HD N automated transmission, the ISX12N natural gas engine is available with a rating of 400 horsepower and 1,450 lb-ft torque and can operate with 100% compressed natural gas (CNG), liquid natural gas (LNG) or renewable natural gas (RNG). This reduces smog-forming NOx emissions by 90% compared to the current Environmental Protection Agency (EPA) standard. When operated using RNG, the system is credited with a neutral to negative carbon index, resulting in net greenhouse gas (GHG) emissions at or below zero.

The new Endurant HD N automated transmission was optimized for integration with the ISX12N natural gas engine and features new software functionality and calibrations, and a new diaphragm spring clutch designed to meet the load requirements of the natural gas engine while protecting the engine for optimal performance.

The integration between the engine and transmission results in improved launch performance, improved low-speed maneuverability and smoother shifts when compared to previous natural gas engines and automated manual transmission combinations.

Inquiries regarding OEM availability may be made with your preferred OEM or dealer.

About Cummins Inc.

Cummins Inc., a global power leader, is a corporation of complementary business segments that design, manufacture, distribute and service a broad portfolio of power solutions. The company’s products range from diesel, natural gas, electric and hybrid powertrains and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, controls systems, air handling systems, automated transmissions, electric power generation systems, batteries, electrified power systems, hydrogen generation and fuel cell products. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 57,800 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $1.8 billion on sales of $19.8 billion in 2020. Learn more at cummins.com.

About Eaton Cummins Automated Transmission Technologies

Eaton Cummins Automated Transmission Technologies is a 50/50 joint venture between Eaton (NYSE: ETN) and Cummins, Inc. (NYSE: CMI). The global joint venture produces and markets industry-leading, heavy-duty automated transmissions for commercial vehicles. For more information visit www.eatoncummins.com.

About Cummins Westport Inc.

Cummins Westport Inc. designs, engineers and markets 5.9 to 12 liter spark-ignited natural gas engines for North American commercial transportation applications such as trucks and buses. Cummins Westport is a joint venture of Cummins Inc. (NYSE:CMI), a corporation of complementary business units that design, manufacture, distribute and service engines and related technologies, including fuel systems, controls, air handling, filtration, emission solutions and electrical power generation systems, and Westport Fuel Systems Inc. (NASDAQ: WPRT / TSX: WPRT), a global leader in alternative fuel, low-emissions technologies that allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), Propane (LPG), hydrogen, and biofuels such as landfill gas.

Jon Mills

Director – External Communications

(317) 658-4540

[email protected]

KEYWORDS: United States North America Indiana

INDUSTRY KEYWORDS: Manufacturing Other Transport Public Transport Trucking Other Energy Transport Utilities Other Manufacturing Oil/Gas Alternative Energy Energy

MEDIA:

Logo
Logo
Posted on

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021

•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET

Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its fourth quarter and year-end financial results on Monday, March 15th. Corbus management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, who will be joined by additional members of the Corbus management team. Interested participants and investors may access the conference call by dialing (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com and will be archived for 90 days Following the event.

About Corbus 

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform. 

Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here. 

For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook. 

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Contacts:

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: [email protected]

Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: [email protected]



Posted on

Xeriant Forming Strategic Alliance with Award-Winning AI Company, TheIncLab

Alliance to Accelerate Development and Commercialization of Next-Gen Aerospace Technologies

BOCA RATON, Fla., March 08, 2021 (GLOBE NEWSWIRE) — Xeriant, Inc. (OTC PINK: XERI), a new aerospace technology holding company, announced today that it has signed a letter of intent to form a strategic alliance with Mente Systems Inc. (DBA TheIncLab), an award-winning artificial intelligence (AI) company based in McLean, Virginia, and a leading innovator in the development of AI-enabled systems focused on the human experience, called AI+X. As part of the agreement, Xeriant plans to make a strategic investment in TheIncLab as it expands its operations and array of technology products.

Established in 2015, TheIncLab designs and builds rapidly deployable, intelligent systems that optimize the interface between humans, technology, data and the environment, serving Fortune 500 companies in a wide range of industries, including aerospace and defense customers. Among its clients are the U.S. Navy’s Office of Naval Research and Special Operations Command, the Johns Hopkins Applied Physics Laboratory, Samsung, NuVasive and Corning. Xeriant plans to work with TheIncLab to assess and maximize the impact of disruptive aerospace technologies and develop a strategy for accelerating their path to integration and commercialization, including advanced VTOL (vertical takeoff and landing) vehicles, a particular area of focus and expertise shared by both companies.

“TheIncLab has an unparalleled record of developing innovative, AI-powered solutions to improve enterprise functions, and having them as a strategic partner will be a critical asset as we move forward and expand our portfolio of acquisitions. We plan on using AI-based modeling as a decision-making support arm to evaluate technologies, product lifecycles, intellectual property, business valuations, sales projections, market size, synergies and risk profiles related to future acquisitions. Their involvement with the aerospace and defense sector brings invaluable insight as we begin to explore AI-based generative design, engineering and prototyping for new aircraft concepts,” commented Keith Duffy, CEO of Xeriant, Inc.

TheIncLab is continuing its work on prototyping cockpit concepts and AI-enabled systems for the Future Vertical Lift (FVL) program, a research and development initiative dedicated to the modernization of the U.S. Armed Forces’ vertical lift fleet, initially targeting the replacement of the Black Hawk helicopter by 2035. The goal of FVL is the design and development of next-generation, technologically advanced manned and unmanned VTOL-capable aerial vehicles with improved maneuverability, range, speed, payload, survivability, reliability, and reduced logistical footprint compared with existing military helicopters.

“As a strategic partner, Xeriant can achieve cross-pollination of technologies across its many organizations, allowing for stronger cohesion and gains across its network of companies. Our AI experience with evaluating and integrating emerging technologies sets the stage for a valuable and mutually beneficial relationship between TheIncLab and Xeriant. Through our talented multi-disciplinary team, we leverage the power of AI to deliver tangible solutions and business value to our clients,” stated Adriana Avakian, Founder and CEO of TheIncLab.

The role of AI in the aerospace industry continues to expand as companies streamline business processes and integrate new and transformative technologies. AI harnesses the power of digitization and data analytics to drive efficiency and innovation, augmenting and extending human capabilities in a range of aerospace applications impacting everything from supply chain management to customer relations. According to a July 2020 report by Grand View Research, the global artificial intelligence market size was valued at USD $39.9 billion in 2019 and is expected to reach USD $733.7 billion by 2027, expanding at a CAGR of 42.2%. PwC estimates that AI will generate over $15 trillion in global GDP gains over the next decade, with half the gains coming from increased worker productivity.

About Mente Systems Inc. (TheIncLab)

Founded in 2015, TheIncLab is the first human-centered artificial intelligence experience (AIX) lab. TheIncLab’s award-winning, multi-disciplinary team is focused on designing and developing AI-enabled systems that learn and collaborate with humans. The company offers its clients comprehensive capabilities for rapid ideation, software development and building of smart systems and hardware solutions. Its open, scalable AI architecture approach, combined with years of experience in interactive engineering and emerging technology innovation, allows for rapid prototyping and deployment of transformational concepts, products and solutions designed to work with meaningful human interaction, effectively bridging the gap between humans and intelligent systems. TheIncLab’s MenteAI product, an open edge framework, allows companies to quickly innovate and build custom interfaces that bridge and augment the interaction of people with AI- enabled systems. Adriana Avakian was recently named to the 2021 Forbes Next1000 List of Upstart Entrepreneurs who are Redefining the American Dream.

About Xeriant

Xeriant, Inc. (d.b.a. Xeriant Aerospace) is a holding and operating company focused on acquiring, developing, and commercializing revolutionary, eco-friendly technologies with applications in aerospace, including innovative aircraft concepts targeting emerging opportunities within the aviation industry. In 2019, Xeriant acquired a unique, scalable, multi-purpose VTOL aerial platform called Halo, which is protected under a broad utility patent. Xeriant is located at the Research Park at Florida Atlantic University in Boca Raton, Florida adjacent to the Boca Raton Airport. The Company is an OTC Markets public company trading under the stock symbol, XERI. 

For more information, please go to www.xeriant.com

SAFE HARBOR FORWARD-LOOKING STATEMENTS

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Xeriant, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations concerning our ability to attract investors.

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

XERIANT, INC. CORPORATE

Investor Relations:
Matt Chipman
(818) 923-5302
[email protected]
www.xeriant.com



Posted on

Iteris Initiates Review of Strategic Alternatives

Iteris Initiates Review of Strategic Alternatives

Board has Engaged Moelis & Company as Financial Advisor to Assist in its Review

SANTA ANA, Calif.–(BUSINESS WIRE)–
Iteris, Inc. (NASDAQ: ITI), the global leader in smart mobility infrastructure management, today announced that its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value.

“Given Iteris participates in a large and dynamic market with multiple opportunities, the Iteris Board of Directors has decided to initiate a comprehensive review of strategic alternatives to maximize shareholder value,” said Tom Thomas, Chairman of the Board of Iteris. “To assist in this strategic review, Iteris has retained Moelis & Company as its financial advisor to review the Company’s strategy and propose potential, additional opportunities to enhance our value and market position.”

Joe Bergera, President and CEO of Iteris added, “Over just the past two years, we have rationalized Iteris’ product portfolio, optimized the Company’s capital structure, and improved our operations. This strategic review will ensure we continue to have the right strategy to deliver both the best solutions for our customers and the strongest returns for our shareholders.”

No assurances can be given regarding the outcome or timing of the review process. Iteris does not intend to make any further public comment regarding the review until it has been completed or the Company determines that disclosure is required or beneficial.

In addition to Moelis & Company serving as financial advisor to Iteris, Latham & Watkins LLP is serving as the Company’s legal advisor.

About Iteris, Inc.

Iteris is the global leader in smart mobility infrastructure management – the foundation for a new era of mobility. We apply cloud computing, artificial intelligence, advanced sensors, advisory services and managed services to achieve safe, efficient and sustainable mobility. Our end-to-end solutions monitor, visualize and optimize mobility infrastructure around the world to help ensure that roads are safe, travel is efficient, and communities thrive. Visit www.iteris.com for more information and join the conversation on Twitter, LinkedIn and Facebook.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release may contain forward-looking statements, which speak only as of the date hereof and are based upon our current expectations and the information available to us at this time. Words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “can,” and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about the Company’s anticipated demand and growth opportunities, conversion of bookings to revenue, the impact and success of new solution offerings, the Company’s recent acquisition, our future performance, growth and profitability, operating results, and financial condition and prospects. Such statements are subject to certain risks, uncertainties, and assumptions that are difficult to predict and actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that may cause such a difference include, but are not limited to: potential impacts on our business and our stock price of consideration or consummation of any strategic alternatives; federal, state and local government budgetary issues, spending and scheduling changes, funding constraints and delays, including in light of the COVID-19 pandemic; the timing and amount of government funds allocated to overall transportation infrastructure projects and the transportation industry; our ability to replace large contracts once they have been completed; the effectiveness of efficiency, cost, and expense reduction efforts; our ability to achieve anticipated benefits from our sale of our Agriculture and Weather Analytics segment; our ability to successfully complete and integrate acquired assets and companies; our ability to specify, develop, complete, introduce, market and gain broad acceptance of our new and existing product and service offerings; risks related to our ability to recruit and/or retain key talent; the potential unforeseen impact of product and service offerings from competitors, increased competition in certain market segments, and such competitors’ patent coverage and claims; any softness in the markets that we address; adverse effects of the COVID-19 pandemic on our vendors and our employees; and the impact of general economic and political conditions and specific conditions in the markets we address, and the possible disruption in government spending and commercial activities, such as the COVID-19 pandemic, import/export tariffs, terrorist activities or armed conflicts in the United States and internationally. Further information on Iteris, Inc., including additional risk factors that may affect our forward-looking statements, as contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, and our other SEC filings that are available through the SEC’s website (www.sec.gov).

For investor inquiries:

Iteris Contact

Douglas Groves

Senior Vice President and Chief Financial Officer

Tel: (949) 270-9643

Email: [email protected]

For media inquiries:

Sard Verbinnen & Co

John Christiansen/Matt Reid

Tel: (415) 618-8750/(310) 201-2040

[email protected]

Iteris Contact

Pierre-André Rebeyrat

Senior Vice President, Marketing

Email: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Internet Data Management Mobile/Wireless Other Technology Technology

MEDIA:

Posted on

IGNITE INTERNATIONAL BRANDS Announces the Appointment of a New Director and Four New Members to its Senior Management Team

IGNITE INTERNATIONAL BRANDS Announces the Appointment of a New Director and Four New Members to its Senior Management Team

VAUGHAN, Ontario–(BUSINESS WIRE)–
IGNITE International Brands, Ltd. (CSE:BILZ, OTCQX: BILZF) (“IGNITE” or the “Company”), is pleased to announce today the appointment of Ms. Vered Elkouby Nisim, as an independent, non-executive director, to its board of directors. Ms. Nisim has extensive marketing experience including work with JH Design Group, a US leading manufacturer of licensed products including iconic brands such as the NFL, NBA, MLB, NHL, NASCAR, Marvel, and many more. Ms. Nisim is also the founder of Brellascope, a cutting-edge boutique marketing firm specializing in unique branding strategies and custom marketing solutions. Ms. Nisim has extended her business experience into cannabis as a member of local and state cannabis associations, committees and boards in California and is Founder/Managing Partner, Curagenics, LLC, a company using leading-edge bio-delivery systems to bring the health benefits of CBD to people for pain management, anxiety and several other physical and neurological conditions.

Ignite is also pleased to announce the following appointments to its executive and leadership teams:

  • Paul Holden has joined the team as General Counsel and Corporate Secretary. Mr. Holden joins Ignite from the Molson Coors organization where he served in various legal roles including Vice President, Legal & Industry Affairs at Molson Coors Canada and Head of Legal & Corporate Affairs at Truss Beverages (a cannabis infused beverage joint venture between Molson Coors and HEXO Corp).
  • Lee Probst has joined the team to lead the sales charge for Ignite as Vice President, Sales. Mr. Probst graduated from Florida State University with a B.S. in Business Management. Over the past 16 years he has been a leader in Sales, Marketing and Operations within the Sports Nutrition Industry.
  • Manuel Gonzalez will join the team as Vice President, International Business Development and will be joining Ignite in early April. Prior to Ignite, Mr. Gonzalez spent the past 21 years expanding global distribution networks for both apparel and vape companies while also establishing a company in France that trains sales executives on how to expand businesses’ penetration from local to European Union in scope.
  • Zach Gleason joins Ignite as Vice President, Distribution. Mr. Gleason started his career manufacturing and distributing eLiquid in 2013. In 2015 he became Vice President of Marina Vape and carried that position until 2019 introducing brands such as AQUA, Alternativ, and Alpha Vape to the market. Just prior to joining Ignite, Mr. Gleason was President of Higher Connection, a Master Distribution company focused on bringing nicotine products to market. Higher Connection was one of the first distributors to introduce Ignite’s synthetic nicotine products to the marketplace.

John Schaefer, the Company’s President and Chief Operating Officer, stated “the addition of Ms. Nisim to Ignite’s Board of Directors adds significant marketing experience and skills to help the Company as it expands its business throughout the United States. The addition of Manuel Gonzalez with his experience in global distribution will help the Company expand globally. The addition of Lee Probst will help manage the Company’s expected sales growth in the United States. The addition of Zach Gleason will help the Company continue its high sales growth in the nicotine vape markets as it continues to responsibly penetrate the adult electronic cigarette market. Finally, Paul Holden’s expertise in spirits and cannabis will help the Company introduce its new Vodka and Tequila products globally and assist in the Company’s expanding cannabis business in Canada.”

The company further announces the granting of options to purchase 900,000 subordinate voting shares to certain employees, officers, directors and consultants of Ignite. The subordinate voting shares will vest over three (3) years from the date of grant and will have an exercise price of $1.10 per share. Based on certain changes in personnel the Company has cancelled options to purchase 650,000 subordinate voting shares.

About IGNITE

IGNITE is a global consumer brand, operating in the premium product segment of the market. Founded by Dan Bilzerian, the Company’s ‘quality‐first’ approach is fundamental to the brand and its products. IGNITE product categories now include CBD products, nicotine and synthetic nicotine vape products, premium performance drinks named ZRO, spirits featuring a premium vodka, and apparel. The IGNITE THC product line was introduced in Canada in 2020.

Shares of IGNITE are listed on the Canadian Securities Exchange (CSE) under the symbol “BILZ” and quoted in the United States on the OTCQX under the symbol “BILZF”.

Further information on IGNITE can be found on the Company’s website at ignite.co.

CAUTIONARY STATEMENT REGARDING FORWARD‐LOOKING INFORMATION

This news release includes certain “forward‐looking statements” under applicable Canadian securities legislation. Forward‐looking statements include, but are not limited to, statements with respect to IGNITE’s ability to expand its business, drive higher sales and penetrate the electronic cigarette and spirits market. Forward‐looking statements are necessarily based upon several estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward‐looking statements. There can be no assurance that any of the forward‐looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐looking statements. The Company disclaims any intention or obligation to update or revise any forward‐looking statements, whether because of new information, future events or otherwise, except as required by law.

Paul A. Holden, General Counsel

Tel: 416-407-1795

Email: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Entertainment Specialty Other Entertainment Food/Beverage Alternative Medicine Health Agriculture Retail Natural Resources Online Retail

MEDIA:

Posted on

TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), to its Board of Directors.

“We are very pleased to welcome Lisa to TRACON’s Board of Directors,” said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. “She is a physician who has focused the majority of her career on the commercialization of innovative products, including Gardasil® and Singulair® at Merck, prior to her appointment as Head of the Global Commercial Operations at GSK. Her strong track record of successful strategic, operational and financial management, combined with her vast commercial experience will be invaluable to TRACON as we execute on our plan to complete clinical development and potentially commercialize envafolimab in the United States in 2023.”

Dr. Johnson-Pratt brings more than two decades of broad business and commercialization leadership experience to TRACON. Dr. Johnson Pratt currently serves as Sr. Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) which is focused on discovering, developing and commercializing RNA-targeted therapeutics for a broad range of diseases. Dr. Johnson-Pratt joined Ionis following its acquisition of Akcea Therapeutics, where she was an Executive Council Member and led an integrated medical team responsible for the commercialization strategy of two novel late stage antisense assets. Prior to that, Dr. Johnson-Pratt was Head of Global Pharma Commercial Operations at GSK. During her time at GSK, she also served as Head of Early Pipeline Commercial Strategy supporting assets in early-stage development across multiple therapeutic areas, including oncology. From 1996 to 2013, Dr. Johnson-Pratt held clinical development and commercial leadership roles at Merck & Co., Inc. During this time, she led global marketing strategy, country operations and global band management teams. Her career has spanned globally, including time in China and Vietnam, supporting products that have contributed strongly to improving patient health for vulnerable patients. Dr. Johnson-Pratt received her medical degree and completed her residency in Internal Medicine, from Howard University. She completed a Fellowship in Clinical Pharmacology and Pharmaceutical Medicine at Howard University. She holds a Diploma of Pharmaceutical Medicine from the Royal College of Physicians. Dr. Johnson-Pratt is the Founder of Ananias Ventures which supports projects focused on issues related to vulnerable women and children, and is on the board of Young People in Recovery (YPR) a national non-profit that supports young people to thrive after recovering from substance abuse.

“TRACON has a first-class management team, an efficient platform to conduct global clinical trials, and a promising drug candidate with near-term commercial potential in envafolimab,” said Dr. Johnson-Pratt. “I am thrilled to support TRACON’s mission to commercialize envafolimab and address significant unmet needs in patients with cancer.”

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.  To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Forward-Looking Statements

Statements made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding TRACON’s and its collaboration partners’ plans to further develop product candidates, expectations regarding the timing and scope of clinical trials and availability of clinical data, expected development, regulatory and commercial milestones and timing thereof, potential utility of product candidates, and TRACON’s business development strategy and goals to enter into additional collaborations. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development and regulatory approval of novel pharmaceutical products; whether TRACON or others will be able to complete or initiate clinical trials on TRACON’s expected timelines, if at all, including due to risks associated with the COVID-19 pandemic; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; the fact that TRACON has limited control over whether or when third party collaborators complete on-going trials or initiate additional trials of TRACON’s product candidates; the fact that TRACON’s collaboration agreements are subject to early termination; whether TRACON will be able to enter into additional collaboration agreements on favorable terms or at all; potential changes in regulatory requirements in the United States and foreign countries; TRACON’s reliance on third parties for the development of its product candidates, including the conduct of its clinical trials and manufacture of its product candidates; whether TRACON will be able to obtain additional financing; and other risks described in TRACON’s filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Company Contact: Investor Contact:
Mark Wiggins Andrew McDonald
Chief Business Officer LifeSci Advisors LLC
(858) 251-3492 646-597-6987

[email protected]
[email protected]



Posted on

IIROC Trading Halt – AGRA

Canada NewsWire

VANCOUVER, BC, March 8, 2021 /CNW/ – The following issues have been halted by IIROC:

Company: AgraFlora Organics International Inc.

CSE Symbol: AGRA

All Issues: Yes

Reason: At the request of the Company Pending News

Halt Time (ET): 7:55 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

Hologic Announces Multi-year Initiative to Improve Quality of Life and Life Expectancy of Women Worldwide

Hologic Announces Multi-year Initiative to Improve Quality of Life and Life Expectancy of Women Worldwide

New Global Women’s Health Index Conducted through Gallup’s World Poll to Benchmark State of Women’s Health in More than 115 Countries

MARLBOROUGH, Mass.–(BUSINESS WIRE)–
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a collaboration with leading analytics and consulting firm Gallup, Inc. on the creation of the Hologic Global Women’s Health Index, the largest and most comprehensive assessment of women’s health in the world.

This multi-year initiative is the first survey to track critical markers of women’s health and safety by country over time. It will include individual responses from more than 120,000 people across 116 countries and in 40 languages. Through a series of targeted questions, the Hologic Global Women’s Health Index will provide unique insight on reproductive health, domestic violence, preventive care, access to care and early disease detection. Hologic conducted the survey as part of Gallup’s World Poll, the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 90% of the world’s adult population through annual, nationally representative surveys with comparable metrics across countries.

“In our ongoing work to support women’s health around the world, we’ve struggled to find comprehensive data that measures progress on key issues like access and quality of care on a global scale,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “Beginning in 2019, we started working with Gallup to develop the Global Women’s Health Index to fill this critical need for a data-driven approach to women’s health. Particularly now, as longstanding disparities in healthcare are exacerbated by the COVID-19 pandemic, we hope that the upcoming findings will shine a spotlight on the need to redefine policies and put women at the center of post-pandemic responses and health systems moving forward.”

Hologic and Gallup developed survey questions for the Global Women’s Health Index under the guidance of global women’s health experts and thought leaders from leading institutions such as Johns Hopkins University, George Washington University, RAD-AID, and Popper and Co., among others.

“Women’s health is not just a women’s issue, it’s a human issue,” said Susan Harvey, MD, FSBI, Vice President of Global Medical Affairs, Breast & Skeletal Health, Hologic. “It is well established that women’s health serves as a marker for social progress, as well as economic stability. When women are healthy, their families are more stable as are the communities around them and the socioeconomic environment overall. The Hologic Global Women’s Health Index will bring awareness to the most pressing health issues facing women globally by offering unique regional insights and the ability to benchmark annually to track changes over time.”

To ensure a comprehensive view of women’s health, the index will feature country-level reports as well as rankings of how countries around the world fare on key indicators of women’s health.

“Since launching in 2005, our Gallup World Poll has evolved to provide information that’s critical to understanding the behavior of the world’s population,” said Jim Clifton, Gallup’s Chairman and Chief Executive Officer. “Through our partnership with Hologic, we’ve highlighted eight essential questions to provide meaningful data on women’s health. We hope leaders around the world will use our metrics to correct inequalities and improve women’s health everywhere.”

The Hologic Global Women’s Health Index will be published later this year. For more information please visit womenshealthindex.com

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and the Global Women’s Health Index are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

About the Gallup World Poll

The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 90% of the world’s adult population through annual, nationally representative surveys with comparable metrics across countries. Gallup, Inc. works with organizations across multilaterals, NGOs, private foundations, philanthropies and corporations to measure more than 100 crucial issues affecting people’s lives via the World Poll. As a result, the World Poll has become an indispensable tool for global leaders and decision-makers who need to understand the hopes, dreams and behaviors of the people they serve.

Forward Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. There can be no assurance that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.

SOURCE : Hologic, Inc.

Media Contact:

Jane Mazur

508.263.8764 (direct)

585.355.5978 (mobile)

[email protected]

Investor Contact:

Michael Watts

858.410.8588

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Data Management Health Consumer Technology Women General Health

MEDIA:

Logo
Logo
Posted on

Accelerant Acquires Commonwealth Insurance Company of America and Announces Introduction of InSightFull™© Platform in U.S. Market

PR Newswire

LONDON and ATLANTA, March 8, 2021 /PRNewswire/ — Accelerant Holdings (“Accelerant” or the “Company”), the parent company of an underwriting group that specializes in serving a carefully selected and managed network of member managing general agencies and program administrators (“Members”), today announced the acquisition of Commonwealth Insurance Company of America (“CICA”) from Brit Group, a subsidiary of Fairfax Financial (TSX: FFH). CICA is a Delaware domiciled admitted insurance carrier with licenses in 48 states and the District of Columbia. Along with the previously announced formation of Accelerant Specialty Insurance Company (“ASIC”), a surplus lines carrier domiciled in Arkansas, CICA is Accelerant’s second owned statutory entity in the U.S. This acquisition enables the Company to serve its best-in-class Members across both non-admitted and admitted market segments. Accelerant remains rated A- (Excellent) by AM Best within its Financial Size Category.  Accelerant plans to rename CICA as Accelerant National Insurance Company (“ANIC”). 

In conjunction with closing the CICA transaction, Accelerant also finalized the rollout of its proprietary underwriting and analysis platform, Accelerant InSightFull, into the U.S. market. Accelerant InSightFull was initially launched as part of the Company’s European and UK operations and has previously been implemented across Accelerant’s underwriting activities in more than 13 countries. The platform facilitates secure and unabridged data flow from the retail broker to reinsurers and other risk bearing capital. The platform delivers critical information to Members  with clarity and speed. Accelerant InSightFull also provides significant data regarding  claims experience, loss information, premium flow and more, benefiting all the participants in the value chain that Accelerant is disrupting.

“Completing the acquisition of CICA is an important development for our Company,” said Jeff Radke, CEO of Accelerant. “We formed Accelerant with the goal of employing technology and a partnership-oriented approach to provide an enhanced user experience to our Members. Adding an admitted platform to our offerings will enable us to write a broader array of program business in the U.S. market.”

Rich Koehler, Chief Business Officer of Accelerant U.S., added, “Accelerant InsightFull technology is unique to the insurance market as it allows the Company to not only efficiently onboard new Members onto our platform, but to also provide them with data-driven insights enabling their business to achieve greater growth and generate superior underwriting results. Leveraging Accelerant InSightFull, we look forward to helping our U.S. Members drive success.”

Joe Zuk, Operating Partner of Altamont Capital, Accelerant’s private equity sponsor and President of ASIC, stated, “We are building the premier, vertically-integrated platform focused solely on the smaller commercial program administrator market. The technology, insights and support we provide are truly second to none, and we look forward to continuing to grow our property, liability and specialty business through supporting program administrators across the U.S.”

About Accelerant Holdings
The Accelerant companies form an underwriting group specializing in serving a carefully selected and managed network of Members in Europeand the U.S.. Accelerant has an established strategy, and a powerful customer value proposition executed by a proven management team, to utilize seasoned relationships to create and control an attractive insurance portfolio serving small and medium-sized enterprises.The Accelerant Insurance Group has been awarded an AM Best A- (Excellent) rating ensuring our Members and their customers can be confident that Accelerant has the financial strength to support them when they need it most. For more information, please visit accelins.com.

About Altamont Capital Partners
Altamont Capital Partners is a private investment firm based in the San Francisco Bay Area with more than $2.75 billion of assets under management. Altamont is focused on investing in middle market businesses where it can partner with leading management teams to help its portfolio companies reach their full potential. The firm’s principals have significant experience building business success stories across a range of industries, including financial services, healthcare, consumer/retail, industrials, and business services. Within the insurance industry, Altamont is either a current or past investor in McLarens Global Claims Services, Celestite Holdings, Embark General, Kuvare Holdings, and Accelerant Holdings.

MEDIA CONTACT:


Jonathan Keehner, Kate Thompson, Tanner Kaufman

Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/accelerant-acquires-commonwealth-insurance-company-of-america-and-announces-introduction-of-insightfull-platform-in-us-market-301242319.html

SOURCE Accelerant Holdings

Posted on

LiveXLive Opens Auditions For “Self Made”- A New Talent Competition Platform Finding The World’s Next Big Music Artists

Talent Platform Goes Live on Monday, March 8, 2021

Social Media Rooted “Self Made” Democratizes Music Competition to Stardom

Artists Discovered Virtually with Help from Social Media Viewers

PR Newswire

LOS ANGELES, March 8, 2021 /PRNewswire/ — LiveXLive Media (Nasdaq: LIVX) (“LiveXLive”), a global platform for live-stream and on-demand audio, video, and podcast/vodcast content in music, comedy, and pop culture, and owner of PodcastOne, Slacker Radio, React Presents, and Custom Personalization Solutions (“CPS”), announced today that auditions for Self Made, an online digital talent search platform, will launch on Monday, March 8, 2021. If you’re an artist or a band, share a video performing your original song with the hashtag #iamselfmade on TikTok or Instagram to enter. It’s that easy!

Self Made by LiveXLive is the most democratic music talent search in history!

Upon launch of the robust social media outreach program, 8 contestants will be selected from the pool of submissions, on Wednesday, March 17th. The final round for the Grand Prize winner and 3 runners up will occur on March 25th. Fans and followers will award a champion in a most unique way that removes the broadcast politics from selecting a winner. The first round Grand Prize winner will receive an “A&R Starter pack” worth $100,000 to launch their professional career that includes a distribution, publishing, and record deal. The distribution deal will promote the winner’s music through LiveXLive’s flywheel, including digital radio, VOD, podcasting and live streaming. These divisions encourage the interaction between audiences and artists to listen, watch, attend, engage and transact. In addition, an exclusive merchandise line will be created around the show and artists.

All 8 contestants will earn a spot in LiveXLive’s annual “Music Lives” Festival scheduled for March 26th and 27th. The program’s mentors include Eshy Gazit, responsible for the worldwide success of Monsta X and BTS; Sharona Nomder, manager of Israeli pop star Noa Kirel; Brandon Silverstein of S10 Entertainment, who manages the Brazilian global superstar Anitta; Ash Pournouri, who turned Swedish DJ Avicii into a worldwide phenomenon; and Charlie Walk, who has worked with such artists as Taylor Swift, Ariana Grande, The Weeknd, Post Malone, and Shawn Mendes.

“Our partnership with Self Made provides independent artists a singular digital platform and community to showcase their talent, jump-start their careers, and dramatically increase visibility among established artists and loyal fans,” said Robert Ellin, CEO and Chairman of LiveXLive. “Working together with Ash Pournouri and his amazing team, we have created the ultimate democratic music competition where we leave everything in the hands of the talent and the fans.”

Created by Ash Pournouri, the former partner of the late global superstar Avicii, Self Made is an online music competition, community, and platform built to discover and launch the artists of tomorrow. Unlike its competitors, it is not another “American Idol” or “X-Factor.” This is a democratized competition built around social media engagement.

Originally conceived and launched in Sweden, the competition was a smash hit reaching 10% of the total population and breaking viewership records on the country’s largest TV VOD network. Now LiveXLive is bringing this movement to the international stage via their talent relationships, promotional prowess, and comprehensive streaming platform.


To enter and vote
, search the hashtag #iamselfmade on TikTok and Instagram to be part of the most democratic music search in history!

If you’re an artist, share a video performing your original song with the hashtag #iamselfmade on TikTok or Instagram to enter.  Whether you’re a Solo Artist or Band, you’ve got a shot! 

For the music lovers out there, LiveXLive invites fans to decide on the winners. Follow at @GOSELFMADE on Instagram or @GetSelfMade on TikTok to watch the competition. Further details can be found by following @livexlive or go to LiveXLive.com/SelfMade.


About LiveXLive Media, Inc.

Headquartered in Los Angeles, California, LiveXLive Media, Inc. (NASDAQ: LIVX) (the “Company”) (pronounced Live “by” Live) is a leading global all-in-one streaming artist-first platform delivering premium music and entertainment content and live-streams from the world’s top artists, expertly curated streaming radio stations, podcasts, and original video and audio-on-demand content, as well as personalized merchandise, connecting artists to millions of fans every day. The Company has streamed over 1,800 artists since January 2020 and has created a valuable connection between bands, fans, and brands by building long-term franchises in audio, video, podcasting, pay-per-view (PPV), live-streaming, and specialty merchandise. LiveXLive is available on iOS, Android, Roku, Apple TV, and Amazon Fire, and through OTT, Samsung TV, STIRR, Sling, and XUMO, in addition to its own app, online website, and social channels. The Company’s wholly-owned subsidiary PodcastOne, generates more than 2.25 billion downloads per year with 400+ episodes distributed per week across a stable of hundreds of top podcasts. The Company’s other major wholly-owned subsidiaries are LiveXLive, Slacker Radio, React Presents, and Custom Personalization Solutions. For more information, visit www.livexlive.com and follow us on Facebook, Instagram, TikTok, and Twitter at @livexlive.


Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: the Company’s reliance on one key customer for a substantial percentage of its revenue; the Company’s ability to consummate any proposed financing, acquisition or transaction, the timing of the closing of such proposed event, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all, or that the closing of any proposed financing, acquisition or transaction will not occur or whether any such event will enhance shareholder value; the Company’s ability to continue as a going concern; the Company’s ability to attract, maintain and increase the number of its users and paid subscribers; the Company identifying, acquiring, securing and developing content; the Company’s ability to maintain compliance with certain financial and other covenants; the Company successfully implementing its growth strategy, including relating to its technology platforms and applications; management’s relationships with industry stakeholders; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of the Company’s subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 26, 2020, Quarterly Report on Form 10-Q for the quarter ended December 31, 2020, filed with the SEC on February 16, 2021, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements, except as may be required by law. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.


Press Contact:


The Rose Group


[email protected]

424.645.4620
[email protected]
614.226.9542


LiveXLive IR Contact:



[email protected]

310.601.2500

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/livexlive-opens-auditions-for-self-made–a-new-talent-competition-platform-finding-the-worlds-next-big-music-artists-301242297.html

SOURCE LiveXLive Media, Inc.